Loading...
01/11 03:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several risks, including clinical trial dependencies, increased financial losses, and high cash burn. The Q&A section reveals management's lack of clarity on critical metrics, which may increase investor uncertainty. Despite a $50 million offering, ongoing financial challenges and operational risks persist. These factors, combined with competitive market pressures, suggest a negative sentiment towards the company's short-term stock performance.
Net Loss $11.4 million (up from $7.8 million in Q4 2023) - The increase in net loss was primarily due to higher R&D expenses related to clinical trials.
R&D Expenses $9.3 million (up from $6.5 million in Q4 2023) - The increase was primarily due to increased clinical trial costs in the Phase 2b CORAL trial, Phase 2a RIVER trial, and the HAP study, as well as an increase in personnel-related expenses.
G&A Expenses $2.9 million (up from $2.4 million in Q4 2023) - The increase was primarily due to an increase in stock-based compensation and personnel-related expenses.
Cash, Cash Equivalents and Marketable Securities $107.6 million - This included a $50 million unwritten offering completed in December 2024 after positive data readouts.
Cash Burn Expected to be $12 million to $14 million per quarter in Q1 and Q2 2025 - This is based on ongoing trials and feedback from the FDA.
Fully Diluted Shares Outstanding Approximately 137 million shares - This includes approximately 10 million stock options outstanding.
Haduvio Development: Haduvio is now the first and only therapy in clinical development to show a statistically significant reduction in chronic cough across patients with IPF and RCC.
Human Abuse Potential Study: Positive results were reported in the Human Abuse Potential study, confirming nalbuphine's low abuse potential.
RIVER Trial Results: The RIVER trial met its primary endpoint with a statistically significant reduction in 24-hour objective cough frequency.
Market Positioning in RCC: Haduvio is positioned to target patients with refractory chronic cough who have failed prior therapies, addressing a significant unmet need.
Specialty Commercial Sales Model: The company plans to maintain a specialty commercial sales model for Haduvio, focusing on high unmet needs in chronic cough.
Clinical Trial Execution: Three positive data readouts were achieved in 2024, with trials conducted across 11 countries and 75 sites.
Enrollment Success: The company experienced its highest enrollment months in December and January for the IPF chronic cough study.
FDA Meeting Plans: Plans to request an End-of-Phase 2 meeting with the FDA by the end of 2025 to discuss pivotal program and study designs.
Future Data Releases: Upcoming data from the RIVER trial will be presented at the American Thoracic Society meeting in May and the European Respiratory Society Congress in September.
Regulatory Risks: The final determination on whether nalbuphine will remain unscheduled will be made by the FDA and DEA upon approval, which introduces uncertainty regarding regulatory outcomes.
Clinical Trial Risks: The company is dependent on the successful completion of ongoing clinical trials (CORAL and RIVER) and the outcomes of these trials will significantly impact future development and approval of Haduvio.
Financial Risks: The company reported a net loss of $11.4 million in Q4 2024, indicating ongoing financial challenges. Additionally, cash burn is expected to be between $12 million to $14 million per quarter in the first half of 2025.
Market Competition Risks: There is a high unmet need in the chronic cough market, but competition exists with other drugs that have failed in this indication, and the company must demonstrate that Haduvio is superior to existing therapies.
Operational Risks: Increased R&D expenses due to clinical trial costs and personnel-related expenses may strain financial resources and affect operational efficiency.
Clinical Trials: Trevi delivered three positive data readouts: Human Abuse Potential study, Sample Size Re-Estimation, and the CORAL study in chronic cough patients with IPF.
Haduvio Development: Haduvio is positioned as a first-in-class therapy in IPF and potentially best-in-class across chronic cough indications.
FDA Meetings: Planning for an End-of-Phase 2 meeting with the FDA by the end of 2025 to discuss pivotal program and NDA filing.
RCC Program Development: Developing a protocol for the next RCC study and planning to request a meeting with the FDA for input.
Cash Runway: Cash runway guidance into the second half of 2026 remains unchanged.
Cash Burn: Expected cash burn of about $12 million to $14 million per quarter in Q1 and Q2 of 2025.
Financial Position: As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $107.6 million.
Cash, cash equivalents and marketable securities: $107.6 million as of December 31, 2024.
Unwritten offering: $50 million unwritten offering completed in December 2024.
Cash burn guidance: Expected cash burn of about $12 million to $14 million per quarter in Q1 and Q2 of 2025.
Fully diluted shares outstanding: Approximately 137 million shares.
The earnings call presents a mixed sentiment. Financial performance is stable with a cash runway into 2028, but increased expenses and lack of clear guidance on critical studies raise concerns. The Q&A session highlights positive interest from the medical community and strategic planning, yet management's vague responses on potential risks and uncertainties, like orphan drug designation, dampen optimism. Given these factors, the stock price is likely to remain neutral in the short term, with no significant catalysts for a strong movement.
The earnings call summary presents a mixed picture: strong financial metrics and consistent trial progress are positive, but uncertainties in FDA meetings and potential DEA scheduling issues pose risks. The Q&A highlights no significant changes or new hurdles, maintaining a stable outlook. Without clear market cap data, the stock reaction is likely neutral.
The earnings call highlights several concerns: increased net loss due to R&D expenses, ongoing cash burn, and significant competition in the chronic cough market. Although the company has a substantial cash position, the high cash burn rate and financial risks are concerning. The Q&A session did not provide reassuring insights, with management lacking clarity on key trial metrics. Despite a completed $50 million offering, the financial outlook remains challenging. These factors suggest a negative sentiment towards the stock's short-term performance.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
